MS clinical trial to focus on people who can’t walk
The first multiple sclerosis (MS) clinical trial to focus only on people who can’t walk is to start recruiting, following funding from an NIHR and MRC partnership.
The ChariotMS trial will test whether cladribine tablets (Mavenclad®), already licensed for highly active relapsing MS, can slow the rate of upper limb disability progression in people with advanced MS.
More than 130,000 people live with MS in the UK and to date, clinical trials haven’t included people who are reliant on a wheelchair. Drugs have only been licensed if they improve walking ability. This means there are currently no disease modifying therapies (DMTs) available for the 35-40% of people with MS who need significant help walking.
If successful, ChariotMS could lead to the first MS drug licensed that protects upper limb function.
Professor Klaus Schmierer, from Queen Mary University of London and Barts Health NHS Trust, is leading the trial. He said:
“Finding ways to maintain people’s upper limb function is essential to their quality of life, but until now walking ability has been the only official measurement of whether or not an MS treatment is effective. This has excluded people who depend on a wheelchair from taking part in trials and, as a result, from accessing effective treatment that will help maintain their hand and arm function.”
There are three main types of MS that are diagnosed – relapsing, primary progressive and secondary progressive.
Thanks to research, there are over a dozen licensed DMTs for people with relapsing MS, and two for ‘active’ progressive MS (where new lesions are visible on an MRI). But tens of thousands of people with MS remain without effective treatment.
While cladribine tablets are a highly effective treatment for people with relapsing MS, early data suggest the drug could also be effective in those with advanced MS.
From January 2021, ChariotMS will recruit 200 people with MS who can walk only a short distance with two crutches, or are unable to walk at all but retain some upper limb function. ChariotMS is also the first trial with no upper age limit.
The trial, based at 20 UK centres, is funded by the Efficacy and Mechanism Evaluation (EME) Programme, which is a partnership between the Medical Research Council and National Institute for Health Research, and will receive additional funding from the MS Society, the National MS Society USA, Barts Charity, and Merck Serono. It is supported by the NIHR Clinical Research Network (CRN) through its Neurological Disorders Specialty.
Professor Danny McAuley, Director of the Efficacy and Mechanism Evaluation (EME) Programme – an NIHR and MRC partnership - said:
“This landmark study is hugely important and could offer real benefits for patients with advanced MS, who currently have few treatment options.
“This shows NIHR and MRC’s commitment – through the EME Programme - to invest in research evaluating treatments which can potentially make a step change in healthcare.”
Dr Emma Gray, Assistant Director of Research at the MS Society, said:
“Preserving hand and arm function would unquestionably improve the quality of life of people with MS, helping them to live more independent lives. That’s why we’re so thrilled to help make this important trial a reality.”
Jenny Ferguson, 63, from Norwich, has secondary progressive MS. The former midwife became reliant on a wheelchair around seven years ago, and today her only limb function is in her right arm and hand. She said:
“I worry a lot about losing the use of my right hand – having a fall and fracturing it, for instance. When MS meant I had to stop working, I started painting to save my sanity, and I’m grateful I can still enjoy that. I think without painting there would be virtually no purpose to my day at all. Your life is only worth living if you’re happy with yourself, and being able to do things and have some independence is key to that.
“Having a treatment that could preserve the use of my hand would make such a tremendous difference to my life – it would be huge.”
More information on the study is available on the NIHR Funding and Awards website.
Details of the study are also available on the mssociety.org.uk/chariotms for more information.